Journal Article Review Epublish
PubMed: 40242762 DOI: 10.3389/fimmu.2025.1561719
Where lung cancer and tuberculosis intersect: recent advances.
Front Immunol 16:1561719
Authors: Chunju Fang, Xuanlu He, Fei Tang, Zi Wang, Cong Pan, Qi Zhang, Jing Wu, Qinglan Wang, Daishun Liu, Yu Zhang
Affiliations
- Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
- School of Clinical Medicine, Zunyi Medical University, Zunyi, China.
- School of Biological Sciences, Guizhou Education University, Guiyang, China. Translational Medicine Research Center, eBond Pharmaceutical Technology Co. Ltd. Chengdu, China.
- Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
- Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, China.
- Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China. National Health Commission Key Laboratory of Pulmonary Immune-Related Diseases, Guizhou Provincial People's Hospital, Guiyang, China.
Abstract
Lung cancer (LC) and tuberculosis (TB) represent two major global public health issues. Prior evidence has suggested a link between TB infection and an increased risk of LC. As advancements in LC treatment have led to extended survival rates for LC patients, the co-occurrence of TB and LC has grown more prevalent and poses novel clinical challenges. The intricate molecular mechanisms connecting TB and LC are closely intertwined and many issues remain to be addressed. This review focuses on resemblance between the immunosuppression in tumor and granuloma microenvironments, exploring immunometabolism, cell plasticity, inflammatory signaling pathways, microbiomics, and up-to-date information derived from spatial multi-omics between TB and LC. Furthermore, we outline immunization-related molecular mechanisms underlying these two diseases and propose future research directions. By discussing recent advances and potential targets, this review aims to establish a foundation for developing future therapeutic strategies targeting LC with concurrent TB infection.
MeSH
Lung, Neoplasms, Lung Neoplasms, Tuberculosis, Therapeutics, Infections